Who are Group Hydroxychloroquine and apixaban's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/group-hydroxychloroquine-and-apixaban.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Group Hydroxychloroquine and apixaban — Competitive Intelligence Brief

Group Hydroxychloroquine and apixaban (Group Hydroxychloroquine and apixaban) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: antimalarial immunomodulator + anticoagulant. Area: Immunology / Rheumatology / Cardiovascular.

phase 3 Combination therapy: antimalarial immunomodulator + anticoagulant Hydroxychloroquine: lysosomal pH and immune signaling; Apixaban: Factor Xa Immunology / Rheumatology / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Group Hydroxychloroquine and apixaban (Group Hydroxychloroquine and apixaban) — Universidade do Vale do Sapucai. This combination pairs hydroxychloroquine, an immunomodulator that reduces inflammation and autoimmune activity, with apixaban, an anticoagulant that inhibits Factor Xa to prevent thrombosis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Group Hydroxychloroquine and apixaban TARGET	Group Hydroxychloroquine and apixaban	Universidade do Vale do Sapucai	phase 3	Combination therapy: antimalarial immunomodulator + anticoagulant	Hydroxychloroquine: lysosomal pH and immune signaling; Apixaban: Factor Xa

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: antimalarial immunomodulator + anticoagulant class)

Universidade do Vale do Sapucai · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Group Hydroxychloroquine and apixaban — Competitive Intelligence Brief. https://druglandscape.com/ci/group-hydroxychloroquine-and-apixaban. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab